

(2) State of New Product Development (as of July 31, 2012)

i. Pipeline in Japan
New Molecular Entities

Development code (Generic name)	Category (Indications)	Stage	Origin
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Phase 3	In-house
MP-214 (Cariprazine)	D3/D2 receptor partial agonist (Schizophrenia)	Phase 2b/3	Hungary: Gedeon-Richter
MP-435	C5a receptor antagonist (Rheumatoid arthritis)	Phase 2	In-house
MT-4666	$\alpha 7$ nACh receptor agonist (Alzheimer's disease)	Phase 1	US: EnVivo Pharmaceuticals
MT-3995	Selective mineralocorticoid receptor antagonist (Hypertention)	Phase 1	In-house
MT-1303	Sphingosine-1-phosphate receptor functional antagonist (Multiple sclerosis)	Phase 1	In-house

Additional Indications

Product name (Generic name)	Category (Indications)	Stage	Origin
Venoglobulin IH (Polyethylene glycol treated human normal immunoglobulin)	Human immunoglobulin G (IgG2 deficiency)	sNDA filed (Dec. 1997)	In-house
	(Systemic scleroderma)	Phase 3	
Radicut (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis*)	Phase 3	In-house
Maintate (Bisoprolol)	Selective β 1 blocker (Chronic atrial fibrillation)	Phase 3	In-house
Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Pediatric allergic rhinitis)	Phase 3	Japan: Ube Industries
Telavic (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [genotype2])	Phase 3	US:Vertex
Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus, additional combination)	Phase3	In-house
Remicade (Infliximab [recombinant])	Anti- human TNF α monoclonal antibody (Subtype Behcet's disease)	Phase 3	US:Janssen Biotech
	(Pediatric Crohn's disease)	Phase 3	
	(Severe Kawasaki disease)	Phase 3	
	(Pediatric ulcerative colitis)	Phase 3	
Cholebine (Colestimide(JAN))	Bile acid signal regulation (Type 2 diabetes mellitus)	Phase 2	In-house
	Non-absorbed phosphate binder (Hyperphosphatemia)	Phase 1	

*: Orphan drug designated

ii. Pipelines Overseas

New Molecular Entities

Development code (Generic name)	Category (Indications)	Region	Stage	Origin
MCI-196 (Colestilan(INN))	Non-absorbed phosphate binder (Hyperphosphatemia)	Europe	MAA filed (Aug. 2011)	In-house
MP-146	Uremic toxin adsorbent (Chronic kidney disease)	US, Europe	Phase 3	Japan:Kureha
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Europe	Phase 2	In-house
		US	Phase 1	
GB-1057 (Recombinant human serum albumin)	Recombinant human serum albumin (Stabilizing agent)	US	Phase 1	In-house
TA-8995	CETP inhibitor (Dyslipidemia)	Europe	Phase 1	In-house
MP-124	PARP inhibitor (Acute ischemic stroke)	US, Canada	Phase 1	In-house
MT-3995	Selective mineralocorticoid receptor antagonist (Hypertention)	Europe	Phase 1	In-house
MP-157	Angiotensin Type 2 Receptor agonist (Hypertention)	Europe	Phase 1	In-house
MT-1303	Sphingosine-1-phosphate receptor functional antagonist (Multiple sclerosis)	Europe	Phase 1	In-house
MT-7716	NOP receptor agonist (Alcohol-use disorder)	US	Phase 1	In-house

iii. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee
TA-1790 (Avanafil)	PDE5 inhibitor (Erectile dysfunction)	Europe	MAA filed (Mar. 2012)	US: Vivus
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus)	US	NDA filed (May 2012)	US: Janssen Pharmaceuticals*
		Europe	MAA filed (Jun. 2012)	
	(Obesity)	US, Europe	Phase 2	
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Korea	Phase 3	Korea: Handok Pharmaceuticals
T-0047 (Finategrast)	Cell adhesion inhibitor [$\alpha4\beta7/\alpha4\beta1$ inhibitor] (Multiple sclerosis)	Europe	Phase 2	UK: GlaxoSmithKline
MKC-242	5-HT1A receptor agonist (Insomnia)	US	Phase 2	US: MediciNova
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	France: Cyrenaic
sTU-199 (Tenatoprazole)	Proton pump inhibitor (Gastroesophageal reflux disease)	Europe	Phase 1	France: Negma (Sidem)
TT-138	$\beta3$ receptor agonist (Pollakiuria, urinary incontinence)	US	Phase 1	US: MediciNova
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase 1	Japan: Maruho

*: A pharmaceutical company of Johnson & Johnson

iv. Changes Since Previous Announcement on May 8, 2012

In-house Development

Development code/Product name (Generic name)	Category (Indications)	Region	As of May 8, 2012	As of July 31, 2012
MP-513/Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Japan	Filed	Approved (Jun. 2012)
BK-4SP/Tetrabik (Pertussis-diphtheria-tetanus- inactivated polio combined vaccine)	Vaccine (Prophylaxis of pertussis, diphtheria, tetanus, and poliomyelitis)	Japan	Filed	Approved* (Jul. 2012)
Remicade (Infliximab [recombinant])	Anti-human TNF α monoclonal antibody (Severe Kawasaki disease)	Japan	None	Phase 3 (May 2012)
	(Pediatric ulcerative colitis)	Japan	None	Phase 3 (May 2012)
MP-214 (Cariprazine)	D3/D2 receptor partial agonist (Schizophrenia)	Japan	Phase 2	Phase 2b/3 (May 2012)
MT-1303	Sphingosine-1-phosphate receptor functional antagonist (Multiple sclerosis)	Japan	None	Phase 1 (May 2012)
MT-2832 (Lunacalcipol)	Vitamin D analog (Secondary hyperparathyroidism)	US, Canada	Phase 2	Termination of license agreement

* Co-developed by MTPC and the Research Foundatin for Microbial Diseases of Osaka University (MA holder)

Licensing-out

Development code (Generic name)	Category (Indications)	Region	As of May 8, 2012	As of July 31, 2012
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	US	Phase 3	Filed (May 2012)
		Europe	Phase 3	Filed (Jun. 2012)
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Korea	None	Phase 3 (Jul. 2012)